Thank you for participating in this SHPA webinar. Please take a few minutes to complete our survey. We are interested to hear your feedback on the webinar and appreciate your time and assistance. Your responses are confidential and will be reported in an aggregated, de-identified format. The questionnaire will take approximately 5 minutes to complete.

Participation in this survey is voluntary. By completing the questionnaire, you are providing implied consent for your responses to be used for evaluation purposes.

If you have any questions please contact Kylee Hayward on khayward@shpa.org.au.

This project has ethics approval from the Central Adelaide Local Health Network Human Research Ethics Committee (Reference number: 13647). If you have any concerns about how the study is being conducted or the consent process, please contact the committee on (08) 7117 2229.


Question Title

* 1. Which of the following best describes your primary role?

Question Title

* 2. Please rate your overall satisfaction with this activity:

Question Title

* 3. The information presented during the webinar supported the achievement of each of the learning objectives

Question Title

* 4. Please rate the degree to which this webinar was relevant to your practice:

Question Title

* 5. Please rate the suitability of delivery of this webinar

Question Title

* 6. Please indicate your level of agreement or disagreement with the following statements as related to inflammatory arthritis, inflammatory bowel disease and plaque psoriasis.

Select the responses most consistent with your position both NOW and BEFORE participating in the webinar.

  NOW BEFORE
I have a good knowledge of biologics e.g., efficacy, interactions, side effects.
A reference biologic can be substituted with a biosimilar, and vice versa, provided they are both ‘a-flagged’, the prescriber has not ticked ‘Brand Substitution Not Permitted’ on the prescription and substitution has been discussed with the patient.
Switching programs, between a reference biologic and its biosimilar or between biosimilars, should be agreed by the drug and therapeutics committee in conjunction with clinical teams and other stakeholders.
Multiple switching between reference biologics and their approved biosimilar brands is not recommended.
I am aware of the nocebo effect, when switching from a reference biologic to a biosimilar or when initiating treatment with a biosimilar.

Question Title

* 7. Please rate your level of confidence associated with the areas below.

Select the response for each statement that is most consistent with your confidence both NOW and BEFORE participating in the webinar.

  NOW BEFORE
Providing information to patients about biologics eg, on administration, disposal, monitoring.
Supporting patients on a biologic, including their adherence.
Substituting a biosimilar for a reference biologic.
Discussing the process of biosimilar substitution to patients, including advice to avoid inadvertent multiple switching.

Question Title

* 8. Please indicate how frequently you would do the following:

Select the responses most consistent with what you would do NOW, after participating in the webinar, and what you would have done BEFORE participating in the webinar.

  NOW BEFORE
Provide information on biologics to patients e.g., dosing, treatment plan.
Support and discuss patient adherence to their biologic treatment.
Educate patients about the biosimilar substitution process.
Substitute a biosimilar for a reference biologic.

Question Title

* 9. Are there any areas where you intend to change your practice as a result of this webinar?

Question Title

* 10. How useful will the SHPA bDMARDs quick reference guide be in supporting your practice?

Question Title

* 11. Please indicate whether you are aware of and/or have used the following resources

  I am aware of this resource I have used this resource
Understanding biological medicines, their biosimilars and the PBS
Australian living guideline for the pharmacological management of inflammatory arthritis
CATAG Guiding principles for the governance of biologics and their biosimilars in Australian hospitals

Question Title

* 12. Please provide any other comments you have on the webinar

T